This chapter focuses on the use of intravenous nicotinamide adenine dinucleotide (NAD+), or DPN, as it was called in the older literature, and its clinical uses to date. Although there is additional, voluminous research being conducted on oral preparations of NAD+, these studies are excluded for the most part from this summary. In the 1980s, American physician William Hitt founded a clinic in Mexico to treat addiction, autoimmune disorders, allergies, and viruses with an intravenous delivery of various vitamins and amino acids prescribed for “neurotransmitter rebalancing.” In addition to significantly reduced cravings, study subjects also reported a dramatic reduction in withdrawal symptoms. The results from this pilot study show that levels of plasma TNF-alpha, a biomarker for inflammation and oxidative stress, are higher in alcohol and opiate patients than in healthy patients, and higher in alcohol patients than opiate patients.